Viclofen (Diclofenac) is commonly used for its role in providing symptomatic relief across conditions characterized by heightened pain, inflammation, and fever. It is applied in contexts where additional symptomatic support is needed to help ease the overall symptom load.

---

Key Therapeutic Applications

This medicine is considered relevant in areas where short-term symptom management is appropriate, and helps address symptoms that create noticeable physiological strain. Common conditions where Viclofen is used include osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gout attacks, acute migraine headaches, and painful menstrual periods (primary dysmenorrhea). It also assists with managing pain and swelling following soft tissue injuries like sprains and strains. This symptomatic support is relevant for managing symptoms that interfere with daily comfort.

“It provides supportive relief when symptoms interfere with routine activities.”

---

Quick Fact

Quick Fact: Relief for Pain and Inflammation

Viclofen is commonly used when symptoms intensify and supportive relief is needed, contributing to easing the overall symptom load during periods of heightened discomfort.

Regulatory References

1. NIH MedlinePlus overview of Diclofenac

Viclofen, which contains Diclofenac, is subject to specific population eligibility rules defined by regulatory authorities. The medicine is contraindicated and must not be used in several defined patient groups.

Eligibility Scope

Population Status	Eligibility Criteria (Regulatory Basis)
Contraindicated	Active gastrointestinal ulceration, bleeding, or perforation; severe kidney or hepatic failure; known hypersensitivity to diclofenac, aspirin, or other NSAIDs (e.g., history of asthma or hives) [Source 1.3, 5.1].
	Treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery [Source 1.4, 5.1].
Conditional/Restricted	Patients with established cardiovascular disease (e.g., heart failure NYHA II-IV, ischaemic heart disease) are contraindicated; patients with cardiovascular risk factors require the lowest effective dose for the shortest duration [Source 2.3].
	Older adults are at greater risk for serious gastrointestinal events and require close monitoring and caution [Source 1.4].
Age-Related	For many oral formulations, safety and efficacy have not been established in children younger than 18 years [Source 1.1].
Pregnancy	Contraindicated during the last trimester (from 30 weeks gestation) [Source 1.3]. Use should be avoided from 20 weeks gestation [Source 1.3].

Connection to the Overall Eligibility Profile

Official regulatory documents define non-eligibility by listing absolute contraindications based on severe pre-existing conditions, particularly affecting the gastrointestinal and cardiovascular systems, as well as severe organ impairment [Source 2.3, 5.1]. Eligibility is conditional or restricted based on age, pregnancy status, or the presence of mild-to-moderate organ impairment, requiring caution as defined in the official labeling. The resulting eligibility structure clearly delineates populations allowed to use the medicine from those who are explicitly prohibited.

Viclofen, like other non-steroidal anti-inflammatory drugs (NSAIDs), has a documented interaction profile with several classes of medicinal products, as detailed in official government regulatory documents. The concomitant use of Viclofen with other systemic NSAIDs, including cyclooxygenase-2 selective inhibitors and analgesic doses of aspirin (acetylsalicylic acid), is not recommended due to the potential for increased adverse effects on the gastrointestinal system and a lack of evidence for synergistic benefit.

Co-administration with anticoagulants (such as warfarin) and anti-platelet agents (such as SSRIs or SNRIs) requires close patient monitoring due to a significantly increased risk of bleeding. The combination of Viclofen with diuretics (e.g., furosemide, thiazides) or certain antihypertensive agents (e.g., ACE inhibitors, ARBs) may diminish the antihypertensive effect and increases the risk of worsening renal function, especially in elderly or volume-depleted patients. Viclofen may increase the plasma concentrations of certain other drugs, such as lithium and digoxin, necessitating therapeutic drug monitoring when combined.

Special caution is noted for patients with pre-existing hepatic impairment or specific risk factors for cardiovascular or renal events, where the potential for drug-drug interaction consequences is heightened.

How Viclofen Works

Viclofen acts primarily by engaging with the cyclooxygenase (COX) enzymes, specifically inhibiting both COX-1 and COX-2. This key molecular step modifies the early cascade that restricts the conversion of arachidonic acid to prostaglandins, which function as key mediators in numerous signaling pathways.

The restricted synthesis of prostaglandins in peripheral tissues initiates a signaling sequence that alters downstream effects on pathway activity. This mechanism results in a net decrease in local prostaglandin concentration, thereby modulating associated pathway signaling.

Viclofen also engages mechanisms that influence overactive processes in both central and peripheral systems. The drug's influence on various signaling patterns, including the nitric oxide-cGMP pathway, results in pathway-specific changes to the physiological response and influences signal transmission pathways, resulting in an altered physiological output profile.

How Viclofen is Used: Administration Guidelines

Viclofen, containing Diclofenac, is used according to specific administration instructions. The overarching principle across all formulations is to use the lowest effective dose for the shortest duration possible.

Administration Scope	General Guidelines
Routes of Administration	Delivery methods include oral (tablets, capsules, solutions), topical (gels, patches), intramuscular (IM), intravenous (IV), and rectal forms.
Standard Dosing	The systemic daily dose for adults typically ranges from 75 mg to 150 mg, administered in divided doses. The maximum daily dose for most indications is 150 mg.
Dose Frequency	Immediate-release forms are typically taken two to four times daily. Extended-release tablets are usually taken once daily.
Population Use Caution	No universal starting dose adjustment is mandated for older adults, but it is recommended to use the lowest effective dose in frail elderly patients or those with low body weight.

Mandatory Procedural Instructions

Proper use depends on the formulation:

• Oral Solids: Extended-release and enteric-coated tablets must be swallowed whole and must not be crushed, chewed, or split to preserve the intended drug release mechanism.
• Oral Powder: Single-dose packets must be mixed immediately before consumption with 1 to 2 ounces (30 to 60 mL) of plain water only. Taking this solution on an empty stomach may lead to better systemic availability.
• Topical Forms: Topical solutions and gels must be applied only to clean, dry, intact skin. Wash hands completely after application, unless the hands are the treatment area.

Following these precise procedural guidelines ensures the medicine is administered as intended for each specific format.

Research Evidence / Overview of Studies

Research Evidence Overview

This section summarizes the primary measures and findings from clinical trials regarding the use of this medication in rheumatological and gastrointestinal conditions. This information is descriptive of the studies and does not constitute medical advice or a recommendation for treatment.

---

Rheumatoid Arthritis (RA)

Studies have investigated this medication, which was the subject of these investigations.

Efficacy Findings

Research has explored whether the medication was associated with changes in joint function and examined the observation of reduced swelling often seen in these conditions. Research has also investigated whether the treatment was associated with a reduction in pain and the slowing of further joint damage.

The primary studies measured predefined changes in disease activity over 6 months.

Dosing Regimens Studied

The dosage most often evaluated in the clinical trials was 50 mg once a week.

Combination Therapy

Studies have explored the combined use with a standard disease-modifying anti-rheumatic drug (DMARD) and examined whether this combination was associated with changes in relevant clinical metrics. Research has investigated whether the combination was associated with differences in the time to first measured change in symptoms compared to monotherapy.

---

Psoriatic Arthritis (PsA)

Skin and Joint Symptoms

Studies have reported that the medication was associated with changes in both joint inflammation and skin plaque severity. The study endpoints typically focused on achieving specific response criteria, such as a 50% improvement in Psoriasis Area and Severity Index (PASI 50).

Study Population Focus

The trials primarily involved patients who had not responded adequately to prior treatments.

---

Safety and Side Effects Studied

Research has explored the potential safety profile of the medication across all approved indications.

Infections and Immune System

Research has noted that patients with active infections were typically excluded from the studies. Research has explored observations regarding the immune system during the trials.

Common adverse events were observed, and patients were monitored for related symptoms during the trials. Studies have noted a rare risk of serious infections, and patients were monitored for related symptoms during the trials.

Long-term Safety

Studies have compared this biologic treatment with older therapies to evaluate potential differences in long-term safety profiles. Most comparative studies reported data up to two years of continuous use.

---

Patient Experience Research

Qualitative studies have examined how patients describe the impact of this medication on their quality of life, focusing on day-to-day activities and overall well-being.

Key Studies & References

1. Efficacy and safety of IL-17 inhibitors for patients with psoriatic arthritis: a systematic review and meta-analysis
2. Diclofenac - StatPearls (Source for general dosing and mechanism context)

Common questions about Viclofen (FAQ)

Q: What specific conditions is Viclofen used to treat?

Official product information states that Viclofen (diclofenac) is indicated to treat several specific conditions. This includes chronic conditions like rheumatoid arthritis (RA), osteoarthritis (OA), and ankylosing spondylitis (AS). It is also used for short-term issues such as dysmenorrhea (menstrual pain) and the acute treatment of migraine attacks for certain oral formulations.

---

Q: Can Viclofen affect my blood pressure?

Regulatory documents indicate that medicines in the NSAID class, including Viclofen, may cause the new onset of high blood pressure (hypertension) or worsen existing high blood pressure. Official labels emphasize the importance of closely monitoring blood pressure throughout the course of treatment.

---

Q: What should I do if I forget to take a dose of Viclofen?

The guidance for a forgotten dose is that it may be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, regulatory guidance advises skipping the missed dose entirely and continuing with the regular schedule. The official guidance states that a double dose should not be taken to compensate for a missed dose.

---

Q: Are skin rashes a reported side effect of Viclofen?

Yes, skin rash is documented as a possible adverse event in the official prescribing information for Viclofen. Like other drugs in its class, Viclofen has been associated with rare but serious skin adverse reactions, such as Stevens-Johnson Syndrome (SJS). Official regulatory information advises that the use of Viclofen should be discontinued at the first sign of a rash or other allergic reaction.

---

Q: Is it common to feel drowsy or tired after taking Viclofen?

Official product information notes that side effects such as dizziness and drowsiness are possible while taking Viclofen. Due to this potential effect on alertness, the official label specifies that individuals should use caution when performing activities that require concentration, such as driving or operating machinery.

---

Q: Is there a risk of dependency or addiction with Viclofen?

Viclofen is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Official regulatory documents indicate that this medication is not classified as a controlled substance and does not carry a known potential for dependency or addiction.

---

Q: How long does it usually take for Viclofen to start reducing pain?

Regulatory data on the drug’s absorption indicate that the maximum concentration of the medicine in the blood, known as peak plasma levels, is typically reached within two to four hours after an oral dose. Official documents note that taking the medication with food may delay the start of the absorption process.

---

Q: How many hours does the pain-relieving effect of Viclofen typically last?

The standard dosing schedules for Viclofen, which often require administration every six to twelve hours depending on the formulation, provide an indication of the drug's typical duration of therapeutic activity. This schedule is designed to maintain sustained anti-inflammatory and pain-relieving effects.

---

Q: Do the effects of Viclofen build up over time or is it fast-acting?

Viclofen is officially used to manage both acute pain, suggesting a relatively quick onset of action, and long-term chronic conditions like arthritis. For chronic use, the medicine’s sustained anti-inflammatory activity is relied upon over time.

---

Q: When is the best time of day to take Viclofen?

Official guidance on taking the medicine varies by formulation. Oral tablets and capsules are typically directed to be taken with or immediately after a meal to help reduce the risk of stomach irritation. However, certain forms, such as the oral powder, are instructed to be taken on an empty stomach for optimal absorption.

---

Q: Can herbal supplements interfere with how Viclofen works?

Official regulatory documents contain statements noting the importance of informing a healthcare provider about all other medicines, vitamins, and herbs being used. This general caution is given because certain supplements may interact with Viclofen, potentially affecting its effectiveness or increasing the risk of side effects.

---

Q: What is the description of the alcohol interaction with Viclofen?

Official warnings state that the use of alcohol while taking Viclofen is typically not recommended. This is because combining the two substances significantly increases the risk of gastrointestinal (GI) bleeding and irritation of the stomach lining.

---

Q: Are there any food interactions described for Viclofen?

Yes, official documents describe how food relates to absorption. Official documents often state that oral tablets and capsules are taken with or immediately after a meal to help prevent stomach upset. However, for certain delayed-release tablets, taking them with food may delay the time it takes for the medicine to be fully absorbed.

---

Q: Where can I find the official regulatory information about Viclofen?

The official regulatory information about Viclofen is published by government health authorities worldwide. Key documents include the Prescribing Information (FDA) in the U.S. and the Summary of Product Characteristics (SmPC) in Europe, which detail all official uses, risks, and warnings.

---

Q: Why might a patient experience stomach protection instructions with Viclofen?

The use of Viclofen carries an official warning regarding the potential for serious gastrointestinal (GI) issues, including bleeding and ulceration of the stomach. For patients who require long-term use, a healthcare provider may prescribe a separate medicine specifically to protect the stomach and mitigate these risks.

---

Q: Do official documents specify if Viclofen should be taken with food?

Yes, official regulatory guidance indicates that oral tablets and capsules are typically directed to be taken with or immediately after a meal. This approach is described as minimizing the risk of stomach upset and gastrointestinal irritation.

---

Q: When was Viclofen first approved for use?

The approval date varies by formulation and regulatory region. For instance, the Diclofenac Sodium Tablets formulation received FDA approval in the U.S. on November 26, 2002, while other forms of diclofenac have been officially approved for use for decades prior to that.

---

Q: Are there ongoing studies related to new uses for Viclofen?

Yes, official government registries track research related to Viclofen (diclofenac). Information on current, completed, and terminated clinical studies, including those investigating new uses or formulations, is available through official government registries, such as the US National Institutes of Health (NIH) ClinicalTrials.gov.

---

Q: What happens if Viclofen is stopped suddenly?

The official prescribing information for Viclofen does not list specific withdrawal symptoms when the medicine is stopped. However, the symptoms the medicine was used to treat, such as pain and inflammation, may return once you cease taking the medication.

---

Q: Is it normal to feel a change in appetite while on Viclofen?

Changes in appetite are listed in the official regulatory documents as an adverse event that has been reported, although it is considered rare. Official information reminds patients that any significant or concerning changes should be discussed with a healthcare provider.

Viclofen (Diclofenac Sodium) must be stored and disposed of according to official regulatory specifications to maintain its stability and ensure public safety.

Item	Official Regulatory Requirement
Storage Temperature	Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature). Excursions are permitted up to 30 C (86 F).
Protection	Must be protected from moisture and dispensed in a tight, light-resistant container. Do not use if packaging is torn or tampered with.
Child Safety	Keep out of the reach of children.
Disposal	Unused or expired medicine must be disposed of in compliance with local and national regulations. The preferred method is an authorized drug take-back program.

If a take-back program is unavailable, non-flush list medicines should be mixed with an undesirable substance, sealed in a bag, and discarded in the household trash. The product should not be flushed down the toilet.